A detailed history of Ra Capital Management, L.P. transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 10,872,503 shares of TSHA stock, worth $23 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
10,872,503
Previous 10,872,503 -0.0%
Holding current value
$23 Million
Previous $24.4 Million 10.27%
% of portfolio
0.3%
Previous 0.37%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.04 - $4.17 $22.2 Million - $45.3 Million
10,872,503 New
10,872,503 $24.4 Million
Q1 2024

May 15, 2024

SELL
$1.43 - $3.25 $10.9 Million - $24.7 Million
-7,600,000 Reduced 41.14%
10,872,503 $31.2 Million
Q4 2023

Feb 14, 2024

BUY
$1.33 - $2.88 $24.6 Million - $53.2 Million
18,472,503 New
18,472,503 $32.7 Million
Q3 2023

Nov 14, 2023

BUY
$0.63 - $3.66 $11.6 Million - $67.6 Million
18,472,503 New
18,472,503 $58.4 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $103M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Ra Capital Management, L.P. Portfolio

Follow Ra Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Ra Capital Management, L.P. with notifications on news.